JP2021520392A5 - - Google Patents

Info

Publication number
JP2021520392A5
JP2021520392A5 JP2020554834A JP2020554834A JP2021520392A5 JP 2021520392 A5 JP2021520392 A5 JP 2021520392A5 JP 2020554834 A JP2020554834 A JP 2020554834A JP 2020554834 A JP2020554834 A JP 2020554834A JP 2021520392 A5 JP2021520392 A5 JP 2021520392A5
Authority
JP
Japan
Prior art keywords
amino
triazolo
pyrazolo
pyrimidine
furan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020554834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520392A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/081785 external-priority patent/WO2019196803A1/en
Publication of JP2021520392A publication Critical patent/JP2021520392A/ja
Publication of JP2021520392A5 publication Critical patent/JP2021520392A5/ja
Withdrawn legal-status Critical Current

Links

JP2020554834A 2018-04-08 2019-04-08 A2a受容体アンタゴニストとしてのピラゾロトリアゾロピリミジン誘導体 Withdrawn JP2021520392A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/082140 2018-04-08
CN2018082140 2018-04-08
PCT/CN2019/081785 WO2019196803A1 (en) 2018-04-08 2019-04-08 Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist

Publications (2)

Publication Number Publication Date
JP2021520392A JP2021520392A (ja) 2021-08-19
JP2021520392A5 true JP2021520392A5 (https=) 2022-04-07

Family

ID=68163465

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020554834A Withdrawn JP2021520392A (ja) 2018-04-08 2019-04-08 A2a受容体アンタゴニストとしてのピラゾロトリアゾロピリミジン誘導体

Country Status (15)

Country Link
US (1) US11472811B2 (https=)
EP (1) EP3774813A4 (https=)
JP (1) JP2021520392A (https=)
KR (1) KR20200140849A (https=)
CN (1) CN112313234B (https=)
AU (1) AU2019251148A1 (https=)
BR (1) BR112020020078A2 (https=)
CA (1) CA3095839A1 (https=)
EA (1) EA202092036A1 (https=)
IL (1) IL277744A (https=)
MX (1) MX2020010618A (https=)
SG (1) SG11202009706VA (https=)
TW (1) TW202010500A (https=)
WO (1) WO2019196803A1 (https=)
ZA (1) ZA202005772B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3774813A4 (en) 2018-04-08 2021-11-17 BeiGene, Ltd. PYRAZOLOTRIAZOLOPYRIMIDE DERIVATIVES AS A2A RECEPTOR ANTAGONIST
KR20230049580A (ko) * 2020-03-26 2023-04-13 헵테얼즈 테라퓨틱스 리미티드 트리아졸론 화합물
WO2021191376A1 (en) * 2020-03-26 2021-09-30 Astrazeneca Ab Triazolone compounds
WO2022087146A1 (en) 2020-10-22 2022-04-28 Landos Biopharma, Inc. Lancl ligands
CN113773327B (zh) * 2021-09-13 2022-07-15 八叶草健康产业研究院(厦门)有限公司 一种吡唑并嘧啶并三唑环类化合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60110219T2 (de) 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
MXPA04003277A (es) 2001-10-08 2004-07-23 Hoffmann La Roche Amida del acido 8-amino-?1,2,4?triazolo?1,5-a?piridina-6-carboxilico.
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
ATE461932T1 (de) 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
AU2011306358B2 (en) * 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
WO2012135084A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2017136375A1 (en) 2016-02-05 2017-08-10 Concert Pharmaceuticals, Inc. Deuterated tozadenant
EP3774813A4 (en) 2018-04-08 2021-11-17 BeiGene, Ltd. PYRAZOLOTRIAZOLOPYRIMIDE DERIVATIVES AS A2A RECEPTOR ANTAGONIST
CN110742893B (zh) 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法

Similar Documents

Publication Publication Date Title
JP2021520392A5 (https=)
JP2008534496A5 (https=)
JP2021500345A5 (https=)
ES2923875T3 (es) Moduladores de la vía integrada del estrés
JP2022554169A5 (https=)
RU2008148902A (ru) Производные имидазол-пиримидина для лечения заболеваний, связанных с киназой гликогенсинтазы 3 (gsk3)
JP2013542265A5 (https=)
JP2019504901A5 (https=)
JP2023520843A5 (https=)
JP2009542638A5 (https=)
RU2013126657A (ru) Ингибиторы nampt и rock
JP2012502975A5 (https=)
JP2023525762A5 (https=)
JP2009542721A5 (https=)
JP2016536333A5 (https=)
JP2014523851A5 (https=)
JP2018511587A5 (https=)
JP2016523911A5 (https=)
RU2011127232A (ru) Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний
JP2022552655A5 (https=)
RU2004118719A (ru) Производные пиперидин-2-она и фармацевтические композиции, содержащие такие соединения в качестве активного ингредиента
JP2018530591A5 (https=)
RU2011137399A (ru) Гетероциклическое производное
RU2013133800A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2017500364A5 (https=)